Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Angiogenin as a Molecular Target for the Treatment of Prostate Cancer

Author(s): Shuping Li, Soichiro Ibaragi and Guo-fu Hu

Volume 7, Issue 2, 2011

Page: [83 - 90] Pages: 8

DOI: 10.2174/1573394711107020083

Price: $65

Abstract

Angiogenin (ANG), a 14 kDa angiogenic ribonuclease, is upregulated in human prostate cancers, especially in hormone refractory diseases, and is the highest upregulated gene in Akt-driven prostate intraepithelial neoplasia (PIN) in mice. ANG has been shown to undergo nuclear translocation in both prostate cancer cells and cancer-associated endothelial cells where it binds to the promoter region of ribosomal DNA (rDNA) and stimulates ribosomal RNA (rRNA) transcription. ANG thus plays an essential role in prostate cancer progression by stimulating both cancer cell proliferation and tumor angiogenesis. A variety of ANG antagonists, including its antisense oligonucleotide, siRNA, soluble binding proteins, monoclonal antibody, enzymatic inhibitors, and nuclear translocation blockers, have all been shown to inhibit prostate cancer in various animal models. Accumulating evidence indicates that ANG is a molecular target for prostate cancer drug development.

Keywords: Angiogenin, angiogenesis, prostate cancer, androgen-independence, rRNA transcription, prostate intraepithelial neoplasia, oligonucleotide, chemotherapeutic agents, immunohistochemical, adenocarcinoma, Neomycin, aminoglycoside, synergistic effect, hyperplasia

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy